Recent News

• 01.28.2025 - Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review
• 01.10.2025 - Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6
• 12.12.2024 - Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)
• 11.21.2024 - Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement
• 11.18.2024 - Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)
• 11.13.2024 - Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Recent Filings

• 12.30.2024 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 12.20.2024 - 424B3 Prospectus [Rule 424(b)(3)]
• 12.19.2024 - EFFECT Notice of Effectiveness
• 12.17.2024 - UPLOAD SEC-generated letter
• 12.17.2024 - CORRESP Correspondence
• 12.13.2024 - S-1 General form for registration of securities under the Securities Act of 1933
• 12.05.2024 - D Notice of Exempt Offering of Securities
• 11.22.2024 - 8-K Current report
• 11.22.2024 - EX-99.1 EX-99.1
• 11.22.2024 - 424B5 Prospectus [Rule 424(b)(5)]